Peptides Biosimilars Market Report

Global Peptides Biosimilars Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 08, 2022
  • PAGES：205
  • REPORT CODE：GMM842380
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Peptides Biosimilars market report explains the definition, types, applications, major countries, and major players of the Peptides Biosimilars market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Celltrion

    • Biocon

    • Dr Reddy's Laboratories

    • Teva Pahrmaceutical

    • Samsung Biologics

    • Mylan

    • Pfizer

    • Stada Arzneimittel AG

    • Sandoz

    • Amgen

    By Type:

    • Glucagon

    • Calcitonin

    By End-User:

    • Oncology

    • Chronic Diseases

    • Autoimmune Diseases

    • Blood Disorders

    • Growth Hormone Deficiency

    • Infectious Diseases

    • Other Diseases

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Peptides Biosimilars Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Peptides Biosimilars Outlook to 2028- Original Forecasts

    • 2.2 Peptides Biosimilars Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Peptides Biosimilars Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Peptides Biosimilars Market- Recent Developments

    • 6.1 Peptides Biosimilars Market News and Developments

    • 6.2 Peptides Biosimilars Market Deals Landscape

    7 Peptides Biosimilars Raw Materials and Cost Structure Analysis

    • 7.1 Peptides Biosimilars Key Raw Materials

    • 7.2 Peptides Biosimilars Price Trend of Key Raw Materials

    • 7.3 Peptides Biosimilars Key Suppliers of Raw Materials

    • 7.4 Peptides Biosimilars Market Concentration Rate of Raw Materials

    • 7.5 Peptides Biosimilars Cost Structure Analysis

      • 7.5.1 Peptides Biosimilars Raw Materials Analysis

      • 7.5.2 Peptides Biosimilars Labor Cost Analysis

      • 7.5.3 Peptides Biosimilars Manufacturing Expenses Analysis

    8 Global Peptides Biosimilars Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Peptides Biosimilars Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Peptides Biosimilars Export by Region (Top 10 Countries) (2017-2028)

    9 Global Peptides Biosimilars Market Outlook by Types and Applications to 2022

    • 9.1 Global Peptides Biosimilars Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Glucagon Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Calcitonin Consumption and Growth Rate (2017-2022)

    • 9.2 Global Peptides Biosimilars Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Oncology Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Chronic Diseases Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Autoimmune Diseases Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Blood Disorders Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Growth Hormone Deficiency Consumption and Growth Rate (2017-2022)

      • 9.2.6 Global Infectious Diseases Consumption and Growth Rate (2017-2022)

      • 9.2.7 Global Other Diseases Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Peptides Biosimilars Market Analysis and Outlook till 2022

    • 10.1 Global Peptides Biosimilars Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Peptides Biosimilars Consumption (2017-2022)

      • 10.2.2 Canada Peptides Biosimilars Consumption (2017-2022)

      • 10.2.3 Mexico Peptides Biosimilars Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Peptides Biosimilars Consumption (2017-2022)

      • 10.3.2 UK Peptides Biosimilars Consumption (2017-2022)

      • 10.3.3 Spain Peptides Biosimilars Consumption (2017-2022)

      • 10.3.4 Belgium Peptides Biosimilars Consumption (2017-2022)

      • 10.3.5 France Peptides Biosimilars Consumption (2017-2022)

      • 10.3.6 Italy Peptides Biosimilars Consumption (2017-2022)

      • 10.3.7 Denmark Peptides Biosimilars Consumption (2017-2022)

      • 10.3.8 Finland Peptides Biosimilars Consumption (2017-2022)

      • 10.3.9 Norway Peptides Biosimilars Consumption (2017-2022)

      • 10.3.10 Sweden Peptides Biosimilars Consumption (2017-2022)

      • 10.3.11 Poland Peptides Biosimilars Consumption (2017-2022)

      • 10.3.12 Russia Peptides Biosimilars Consumption (2017-2022)

      • 10.3.13 Turkey Peptides Biosimilars Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Peptides Biosimilars Consumption (2017-2022)

      • 10.4.2 Japan Peptides Biosimilars Consumption (2017-2022)

      • 10.4.3 India Peptides Biosimilars Consumption (2017-2022)

      • 10.4.4 South Korea Peptides Biosimilars Consumption (2017-2022)

      • 10.4.5 Pakistan Peptides Biosimilars Consumption (2017-2022)

      • 10.4.6 Bangladesh Peptides Biosimilars Consumption (2017-2022)

      • 10.4.7 Indonesia Peptides Biosimilars Consumption (2017-2022)

      • 10.4.8 Thailand Peptides Biosimilars Consumption (2017-2022)

      • 10.4.9 Singapore Peptides Biosimilars Consumption (2017-2022)

      • 10.4.10 Malaysia Peptides Biosimilars Consumption (2017-2022)

      • 10.4.11 Philippines Peptides Biosimilars Consumption (2017-2022)

      • 10.4.12 Vietnam Peptides Biosimilars Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Peptides Biosimilars Consumption (2017-2022)

      • 10.5.2 Colombia Peptides Biosimilars Consumption (2017-2022)

      • 10.5.3 Chile Peptides Biosimilars Consumption (2017-2022)

      • 10.5.4 Argentina Peptides Biosimilars Consumption (2017-2022)

      • 10.5.5 Venezuela Peptides Biosimilars Consumption (2017-2022)

      • 10.5.6 Peru Peptides Biosimilars Consumption (2017-2022)

      • 10.5.7 Puerto Rico Peptides Biosimilars Consumption (2017-2022)

      • 10.5.8 Ecuador Peptides Biosimilars Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Peptides Biosimilars Consumption (2017-2022)

      • 10.6.2 Kuwait Peptides Biosimilars Consumption (2017-2022)

      • 10.6.3 Oman Peptides Biosimilars Consumption (2017-2022)

      • 10.6.4 Qatar Peptides Biosimilars Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Peptides Biosimilars Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Peptides Biosimilars Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Peptides Biosimilars Consumption (2017-2022)

      • 10.7.2 South Africa Peptides Biosimilars Consumption (2017-2022)

      • 10.7.3 Egypt Peptides Biosimilars Consumption (2017-2022)

      • 10.7.4 Algeria Peptides Biosimilars Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Peptides Biosimilars Consumption (2017-2022)

      • 10.8.2 New Zealand Peptides Biosimilars Consumption (2017-2022)

    11 Global Peptides Biosimilars Competitive Analysis

    • 11.1 Celltrion

      • 11.1.1 Celltrion Company Details

      • 11.1.2 Celltrion Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Celltrion Peptides Biosimilars Main Business and Markets Served

      • 11.1.4 Celltrion Peptides Biosimilars Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Biocon

      • 11.2.1 Biocon Company Details

      • 11.2.2 Biocon Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Biocon Peptides Biosimilars Main Business and Markets Served

      • 11.2.4 Biocon Peptides Biosimilars Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Dr Reddy's Laboratories

      • 11.3.1 Dr Reddy's Laboratories Company Details

      • 11.3.2 Dr Reddy's Laboratories Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Dr Reddy's Laboratories Peptides Biosimilars Main Business and Markets Served

      • 11.3.4 Dr Reddy's Laboratories Peptides Biosimilars Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Teva Pahrmaceutical

      • 11.4.1 Teva Pahrmaceutical Company Details

      • 11.4.2 Teva Pahrmaceutical Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Teva Pahrmaceutical Peptides Biosimilars Main Business and Markets Served

      • 11.4.4 Teva Pahrmaceutical Peptides Biosimilars Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Samsung Biologics

      • 11.5.1 Samsung Biologics Company Details

      • 11.5.2 Samsung Biologics Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Samsung Biologics Peptides Biosimilars Main Business and Markets Served

      • 11.5.4 Samsung Biologics Peptides Biosimilars Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Mylan

      • 11.6.1 Mylan Company Details

      • 11.6.2 Mylan Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Mylan Peptides Biosimilars Main Business and Markets Served

      • 11.6.4 Mylan Peptides Biosimilars Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Pfizer

      • 11.7.1 Pfizer Company Details

      • 11.7.2 Pfizer Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Pfizer Peptides Biosimilars Main Business and Markets Served

      • 11.7.4 Pfizer Peptides Biosimilars Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Stada Arzneimittel AG

      • 11.8.1 Stada Arzneimittel AG Company Details

      • 11.8.2 Stada Arzneimittel AG Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Stada Arzneimittel AG Peptides Biosimilars Main Business and Markets Served

      • 11.8.4 Stada Arzneimittel AG Peptides Biosimilars Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Sandoz

      • 11.9.1 Sandoz Company Details

      • 11.9.2 Sandoz Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Sandoz Peptides Biosimilars Main Business and Markets Served

      • 11.9.4 Sandoz Peptides Biosimilars Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Amgen

      • 11.10.1 Amgen Company Details

      • 11.10.2 Amgen Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Amgen Peptides Biosimilars Main Business and Markets Served

      • 11.10.4 Amgen Peptides Biosimilars Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    12 Global Peptides Biosimilars Market Outlook by Types and Applications to 2028

    • 12.1 Global Peptides Biosimilars Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Glucagon Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Calcitonin Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Peptides Biosimilars Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Oncology Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Chronic Diseases Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Autoimmune Diseases Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Blood Disorders Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.5 Global Growth Hormone Deficiency Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.6 Global Infectious Diseases Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.7 Global Other Diseases Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Peptides Biosimilars Market Analysis and Outlook to 2028

    • 13.1 Global Peptides Biosimilars Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.2.2 Canada Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Peptides Biosimilars Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.3.2 UK Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.3.3 Spain Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.3.5 France Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.3.6 Italy Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.3.8 Finland Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.3.9 Norway Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.3.11 Poland Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.3.12 Russia Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Peptides Biosimilars Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.4.2 Japan Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.4.3 India Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Peptides Biosimilars Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.5.3 Chile Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.5.6 Peru Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Peptides Biosimilars Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.6.3 Oman Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Peptides Biosimilars Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Peptides Biosimilars Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Peptides Biosimilars Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Peptides Biosimilars Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Peptides Biosimilars

    • Figure of Peptides Biosimilars Picture

    • Table Global Peptides Biosimilars Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Peptides Biosimilars Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Glucagon Consumption and Growth Rate (2017-2022)

    • Figure Global Calcitonin Consumption and Growth Rate (2017-2022)

    • Figure Global Oncology Consumption and Growth Rate (2017-2022)

    • Figure Global Chronic Diseases Consumption and Growth Rate (2017-2022)

    • Figure Global Autoimmune Diseases Consumption and Growth Rate (2017-2022)

    • Figure Global Blood Disorders Consumption and Growth Rate (2017-2022)

    • Figure Global Growth Hormone Deficiency Consumption and Growth Rate (2017-2022)

    • Figure Global Infectious Diseases Consumption and Growth Rate (2017-2022)

    • Figure Global Other Diseases Consumption and Growth Rate (2017-2022)

    • Figure Global Peptides Biosimilars Consumption by Country (2017-2022)

    • Table North America Peptides Biosimilars Consumption by Country (2017-2022)

    • Figure United States Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Canada Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Mexico Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Table Europe Peptides Biosimilars Consumption by Country (2017-2022)

    • Figure Germany Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure UK Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Spain Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Belgium Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure France Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Italy Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Denmark Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Finland Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Norway Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Sweden Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Poland Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Russia Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Turkey Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Table APAC Peptides Biosimilars Consumption by Country (2017-2022)

    • Figure China Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Japan Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure India Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure South Korea Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Thailand Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Singapore Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Philippines Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Table South America Peptides Biosimilars Consumption by Country (2017-2022)

    • Figure Brazil Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Colombia Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Chile Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Argentina Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Peru Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Table GCC Peptides Biosimilars Consumption by Country (2017-2022)

    • Figure Bahrain Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Oman Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Qatar Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Table Africa Peptides Biosimilars Consumption by Country (2017-2022)

    • Figure Nigeria Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure South Africa Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Egypt Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Algeria Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Table Oceania Peptides Biosimilars Consumption by Country (2017-2022)

    • Figure Australia Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Peptides Biosimilars Consumption and Growth Rate (2017-2022)

    • Table Celltrion Company Details

    • Table Celltrion Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celltrion Peptides Biosimilars Main Business and Markets Served

    • Table Celltrion Peptides Biosimilars Product Portfolio

    • Table Biocon Company Details

    • Table Biocon Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biocon Peptides Biosimilars Main Business and Markets Served

    • Table Biocon Peptides Biosimilars Product Portfolio

    • Table Dr Reddy's Laboratories Company Details

    • Table Dr Reddy's Laboratories Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Dr Reddy's Laboratories Peptides Biosimilars Main Business and Markets Served

    • Table Dr Reddy's Laboratories Peptides Biosimilars Product Portfolio

    • Table Teva Pahrmaceutical Company Details

    • Table Teva Pahrmaceutical Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pahrmaceutical Peptides Biosimilars Main Business and Markets Served

    • Table Teva Pahrmaceutical Peptides Biosimilars Product Portfolio

    • Table Samsung Biologics Company Details

    • Table Samsung Biologics Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Samsung Biologics Peptides Biosimilars Main Business and Markets Served

    • Table Samsung Biologics Peptides Biosimilars Product Portfolio

    • Table Mylan Company Details

    • Table Mylan Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mylan Peptides Biosimilars Main Business and Markets Served

    • Table Mylan Peptides Biosimilars Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Peptides Biosimilars Main Business and Markets Served

    • Table Pfizer Peptides Biosimilars Product Portfolio

    • Table Stada Arzneimittel AG Company Details

    • Table Stada Arzneimittel AG Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Stada Arzneimittel AG Peptides Biosimilars Main Business and Markets Served

    • Table Stada Arzneimittel AG Peptides Biosimilars Product Portfolio

    • Table Sandoz Company Details

    • Table Sandoz Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sandoz Peptides Biosimilars Main Business and Markets Served

    • Table Sandoz Peptides Biosimilars Product Portfolio

    • Table Amgen Company Details

    • Table Amgen Peptides Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Peptides Biosimilars Main Business and Markets Served

    • Table Amgen Peptides Biosimilars Product Portfolio

    • Figure Global Glucagon Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Calcitonin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oncology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chronic Diseases Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Autoimmune Diseases Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Blood Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Growth Hormone Deficiency Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Infectious Diseases Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Diseases Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Peptides Biosimilars Consumption Forecast by Country (2022-2028)

    • Table North America Peptides Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure United States Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Peptides Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure Germany Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Peptides Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure China Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Peptides Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure Brazil Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Peptides Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Peptides Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Peptides Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure Australia Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Peptides Biosimilars Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US